CD8A and Guillain-Barre syndrome: The administration of EG00229, a selective NRP1 inhibitor, altered gene expression in microglia, enhancing glioma-specific CD8+ T cell immunity and increasing survival in a mouse model of GBs (Miyauchi et al., 2016).